Document is current
Any future updates will be listed below
-
Authors
Beheshti, Mohsen https://orcid.org/0000-0003-3918-3812
Shahbazi-Akbari, Malihe
Hacker, Marcus
Loidl, Wolfgang
Langsteger, Werner
-
Funding
Funding for this research was provided by:
Telix Pharmaceuticals
Paracelsus Medical University
- License Information
-
More Information
Article History
Received: 19 August 2024
Revised: 7 May 2025
Accepted: 13 May 2025
First Online: 28 May 2025
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was also approved by the local ethics committee with the trial number EKS-10/18 and EudraCT number: 2017–005078-20.
: Informed consent was obtained from all individual participants included in the study.
: Mohsen Beheshti reports a relationship with Novartis Pharma GmbH and Telix Pharmaceuticals that includes board membership and consulting or advisory. Marcus Hacker reports a relationship with Novartis Pharma GmbH that includes board membership and consulting or advisory.
